← TrialMatch
HomeTrials

New AI-based Technologies in Nuclear Medicine

The study aims to identify and predict radiopharmaceutical extravasation events using new semi-quantitative parameters and machine learning models. It involves dose rate measurements to develop metrics for real-time monitoring. It also investigates the correlation between extravasation and SUV correction in PET/CT diag

Condition(s)Patients Undergoing PET/CT Investigation or Nuclear Medicine Therapy
StatusRecruiting
Study typeObservational
SummaryThe study aims to identify and predict radiopharmaceutical extravasation events using new semi-quantitative parameters and machine learning models. It involves dose rate measurements to develop metrics for real-time monitoring. It also investigates the correlation between extravasation and SUV correction in PET/CT diagnostics, providing an estimate of the correction factor necessary for accurate SUV evaluation in case of an extravasation event.
Who can participateInclusion Criteria: * patients undergoing PET/CT scans or therapeutic treatments with radiopharmaceuticals labelled with alpha or beta emitting nuclides Exclusion Criteria: * patients whose clinical or psychological conditions do not allow for their involvement
Ages18 Years to 90 Years
SexAll
Lead sponsorAzienda USL Reggio Emilia - IRCCS
LocationsReggio Emilia, Italy
Start date2021-07-30
NCT IDNCT07174089
Official listinghttps://clinicaltrials.gov/study/NCT07174089

🔍 Search all trials →